Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | ARROW study: pralsetinib in RET fusion+ tumors

Vivek Subbiah, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ARROW study (NCT03037385), which aimed to test the activity of pralsetinib, a selective inhibitor of oncogenic RET alterations in solid tumours. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).